FY2025 EPS Estimates for Biogen Lifted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share estimate for Biogen to $15.93, up from a previous estimate of $15.45. The FY2026 estimate stands at $16.40 EPS.
• Biogen's stock opened at $131.95 and has a market cap of $19.35 billion, with a 12-month price range between $110.04 and $213.50.
• The consensus rating for Biogen is currently "Hold", with 21 analysts recommending a hold and 12 issuing a buy rating.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Biogen in a research report issued to clients and investors on Friday, August 1st. Cantor Fitzgerald analyst E. Schmidt now forecasts that the biotechnology company will post earnings of $15.93 per share for the year, up from their prior estimate of $15.45. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Cantor Fitzgerald also issued estimates for Biogen's FY2026 earnings at $16.40 EPS.

Several other analysts have also recently weighed in on the stock. The Goldman Sachs Group reduced their target price on shares of Biogen from $219.00 to $197.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Canaccord Genuity Group cut their price target on Biogen from $265.00 to $220.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Citigroup upped their price objective on shares of Biogen from $125.00 to $135.00 and gave the stock a "neutral" rating in a research report on Friday, August 1st. Robert W. Baird dropped their target price on Biogen from $300.00 to $255.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Finally, Truist Financial assumed coverage on shares of Biogen in a research report on Monday, July 21st. They issued a "hold" rating and a $142.00 price objective on the stock. Twenty-one equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $185.63.

Biogen Price Performance

NASDAQ BIIB traded down $0.78 on Monday, hitting $128.56. The company had a trading volume of 759,404 shares, compared to its average volume of 1,567,331. The company's fifty day moving average price is $130.10 and its 200-day moving average price is $131.62. Biogen has a 12-month low of $110.04 and a 12-month high of $207.59. The company has a market capitalization of $18.85 billion, a PE ratio of 12.31, a PEG ratio of 1.05 and a beta of 0.13. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.50 and a quick ratio of 1.79.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%. The business had revenue of $2.65 billion for the quarter, compared to analysts' expectations of $2.32 billion. During the same quarter last year, the firm earned $5.28 EPS. The business's revenue for the quarter was up 7.3% on a year-over-year basis.

Institutional Investors Weigh In On Biogen

Large investors have recently added to or reduced their stakes in the business. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Biogen by 6.5% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 416,960 shares of the biotechnology company's stock valued at $57,057,000 after buying an additional 25,464 shares during the period. Asset Management One Co. Ltd. grew its position in Biogen by 5.5% during the 1st quarter. Asset Management One Co. Ltd. now owns 61,420 shares of the biotechnology company's stock worth $8,405,000 after acquiring an additional 3,194 shares during the last quarter. APG Asset Management N.V. grew its holdings in shares of Biogen by 346.1% in the fourth quarter. APG Asset Management N.V. now owns 105,446 shares of the biotechnology company's stock worth $15,572,000 after purchasing an additional 81,811 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Biogen by 3.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 44,796 shares of the biotechnology company's stock valued at $6,130,000 after buying an additional 1,336 shares during the period. Finally, Ilmarinen Mutual Pension Insurance Co increased its position in shares of Biogen by 33.3% in the fourth quarter. Ilmarinen Mutual Pension Insurance Co now owns 24,000 shares of the biotechnology company's stock valued at $3,670,000 after acquiring an additional 6,000 shares during the period. Institutional investors and hedge funds own 87.93% of the company's stock.

Insider Activity

In related news, insider Rachid Izzar sold 2,223 shares of the firm's stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total transaction of $300,105.00. Following the transaction, the insider directly owned 6,330 shares of the company's stock, valued at approximately $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.18% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.